OncoMatch/Clinical Trials/NCT06925737
A Clinical Study of Ifinatamab Deruxtecan (I-DXd) in People With Metastatic Prostate Cancer (MK-2400-001)
Is NCT06925737 recruiting? Yes, currently enrolling (Jun 2026). This Phase 3 trial studies multiple treatments including Ifinatamab deruxtecan and Docetaxel for prostate cancer.
Treatment: Ifinatamab deruxtecan · Docetaxel · Prednisone · Rescue Medication — Researchers are looking for new ways to treat metastatic castration-resistant prostate cancer (mCRPC). Researchers have designed a study medicine called ifinatamab deruxtecan (also called I-DXd or MK-2400) to treat mCRPC. The goal of this study is to learn if people who receive I-DXd live longer overall and live longer without the cancer growing or spreading than people who receive chemotherapy.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Targeted therapy
Chemotherapy
Other
Cancer type
Prostate Cancer
Disease stage
Metastatic disease required
Demographics
Prior therapy
Must have received: androgen receptor pathway inhibitor
Has received prior treatment with 1 or 2 androgen receptor pathway inhibitors (ARPIs) and progressed during or after at least 8 weeks of treatment
Cannot have received: taxane-based chemotherapy
Exception: for metastatic castration-resistant prostate cancer (mCRPC)
Has received prior treatment with a taxane-based chemotherapy agent for metastatic castration-resistant prostate cancer (mCRPC)
Cannot have received: antibody-drug conjugate (exatecan derivative (e.g., trastuzumab deruxtecan))
Exception: prior discontinuation due to treatment-related toxicities
Has had prior discontinuation of an antibody drug conjugate (ADC) that consists of an exatecan derivative (eg, trastuzumab deruxtecan) due to treatment-related toxicities
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Mayo Clinic in Arizona - Phoenix ( Site 0044) · Phoenix, Arizona
- City of Hope Comprehensive Cancer Center ( Site 0049) · Duarte, California
- City of Hope Lennar Foundation Cancer Center ( Site 0059) · Irvine, California
- Moores Cancer Center ( Site 0010) · La Jolla, California
- Cedars-Sinai Medical Center ( Site 0068) · Los Angeles, California
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT06925737 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior taxane-based chemotherapy, antibody-drug conjugate disqualifies patients from enrollment.
Is this trial open to female patients?
No. This trial enrolls male patients only.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages